Videos

“We hope that the survey can be helpful in practice to actually assess and give advice to some of these partners of patients, in addition to the questionnaires that we use for the patients themselves,” says Stacy Loeb, MD, MSc.

"The challenge of treating men with high-risk disease and potential micro metastatic disease with this type of targeted therapy is really exciting," says David I. Lee, MD, FACS.

"We found that, in our study, approximately 25% of patients who have had opioids prior to their cystectomy will continue to use opioids 3 to 6 months after their surgery," says Christopher J. Staniorski, MD.

“At the Advocacy Summit earlier this spring, 2 of the 3 leave-behind documents that outlined specific issues related to urology priorities were directly informed by information from the Census,” says Matthew Nielsen, MD, MS, FACS.

"Questions that arise for us [include] why, and what's further contributing to our observed outcome?" says Devon M. Langston, MD.

Expert urologist explores potential treatments for BCG-unresponsive intermediate and high-risk non-muscle-invasive bladder cancer (NMIBC), including immune checkpoint inhibitors, oncolytic viral therapy, cytokine agonists, immunomodulators, and the recently approved drugs pembrolizumab and nogapendekin alfa inbakicept-pmln.

"We found that during the 5-year study period, the total number of claims for vaginal estrogen, the number of prescribers, and the number of beneficiaries decreased," says Alexandra Tabakin, MD.

“I think my immediate hope and goal with the study finding is universal incorporation of HPV testing on all penile cancer patients,” says Rohan Garje, MD.

"Despite the results of SURTIME and CARMENA, among others, we continue to hear discussions about the role of cytoreductive nephrectomy in conferences and literature, suggesting that this remains a question that has not been fully addressed," says Jaleh Fallah, MD.

“The results of the study showed that regardless of any biomarkers, the combination of pembrolizumab and lenvatinib was superior or associated with a better median progression-free survival compared to sunitinib,” says Jaime R. Merchan, MD.

“We can see that the median survival is going beyond 31 months, meaning that patients with a low tumor burden are benefiting,” says Joaquim Bellmunt, MD, PhD.

"There is a hypothesis that nectin-4 as a potential target for antibody drug conjugates, such as EV, potentially should work," says Marijo Bilusic, MD, PhD.

“So, we split this apart and looked into if the type of progression would occur differently depending on the organ sites, which it did not. What we have seen is maintained benefits for the combination of lenvatinib and pembrolizumab vs sunitinib,” says Viktor Grünwald, MD, PhD.

“My hope is that the DFF332 approach may potentially be one that's palatable in combination with other therapies,” says Sumanta Pal, MD, FASCO.

Focusing on prostate cancer diagnosis, the panel discusses transrectal and transperineal biopsies and limitations associated with them.

The panel discusses the role of PSMA-PET imaging in prostate cancer and highlights different PSMA agents.

Bladder cancer experts discuss the evolving treatment landscape in BCG-unresponsive NMIBC and give an overview of TAR-200, an emerging therapy.

A panel of experts on prostate cancer introduce themselves and begin the discussion with clinical insights on diagnostic practices and the importance of biopsy and imaging in guiding treatment decisions.

A panel of experts on prostate cancer provide an overview of conventional imaging modalities that have been used in the initial staging and management of prostate cancer and discuss the role of PSMA-PET imaging.

A panel of experts on non–muscle invasive bladder cancer (NMIBC) discuss challenges associated with BCG shortages and the impact on treatment options and patients’ quality of life.

In this video, Kevin C. Zorn, MD, FRCSC, FACS, discusses key BPH data from the 2024 American Urological Association Annual Meeting.

"Our study looked at data from 5 trials of the combination therapy with an immune checkpoint inhibitor and the VEGF TKI evaluating if there's still any potential role for cytoreductive nephrectomy that is worth being investigated in prospective studies," says Jaleh Fallah, MD.

"When we reviewed the data, we noticed a large difference in outcomes based on ethnicity," says Devon M. Langston, MD.

"Holistic review is a way to assess an applicant's candidacy for residency by looking at lived experiences and personal attributes in addition to traditional metrics, like Step 1 scores, AOA, and number of research publications," says Alexandra Tabakin, MD.

Gary D. Steinberg, MD, discusses the unmet needs and current standard of care for patients with intermediate and high-risk non-muscle-invasive bladder cancer (NMIBC).

“Variation is the enemy of quality. The more streamlined we can do these things and include APPs in the teachings of procedures and understanding different subspecialties of prostate cancer, I think it would be helpful,” says Joy Maulik, CRNP

“Overall, I think this study will allow clinicians to better advise patients in the slightly complex landscape of OAB therapies,” says Leo Dreyfuss, MD.

"I think [these are] important data to [give to] your patients," says Laura Bukavina, MD, MPH.

Michael S. Cookson, MD, MMHC, FACS, recaps several presentations on prostate cancer from the 2024 American Urological Association Annual Meeting in San Antonio, Texas.

"Anecdotally, I would say that many providers actually prefer the functionality of the single-use cystoscopes," says David Barquin, MD.